E2F1 and cancer: Importantly, with the discovery of a large number of E2F1:coregulator complexes that drive metastasis, patient-specific pharmacogenomics profiling of cofactors combined with small molecule inhibitors identified using pharmacophore modeling approaches may improve personalized cancer therapy.